

Modified Zone 1 to commercial/ industrial standards. A commercial/ industrial remedy is consistent with the contingent remedy described in the Record of Decision Amendment dated March 24, 2020 (the "ROD Amendment"). The ROD Amendment states that, if two conditions are satisfied, the EPA will issue an ESD to confirm that these two conditions have been met and will change the selected remedy for Modified Zone 1 from a residential cleanup to a commercial/ industrial cleanup. On May 26, 2020, the first condition was satisfied when the City of East Chicago changed the zoning designation for Modified Zone 1 from residential to light industrial. The Purchaser intends to acquire title to real property within Modified Zone 1 (the "Property") with the intent to redevelop it for commercial/industrial use. This acquisition will satisfy the second condition. Once the EPA receives notice that the Purchaser has acquired title to the Property, both conditions will be satisfied. The EPA will then issue the ESD and the PPA will become effective. Under the proposed PPA, Purchaser will remediate contaminated soils at the Property to commercial/industrial criteria as required by the ROD Amendment.

Under the proposed ASAOC, Respondents will provide financial assurance for the remedial action to be performed by Purchaser under the PPA, pay future federal and state oversight costs after application of an \$800,000 credit towards those costs, and pay \$18,000,000 in settlement of certain response costs incurred by the EPA at the Site. The Respondents and the Additional Covered Parties also agree to waive potential claims for reimbursement from the Hazardous Substance Superfund under Section 106(b) of CERCLA, 42 U.S.C. 9606(b).

In both the PPA and the ASAOC, the EPA covenants not to sue the Purchaser, Respondents, and Additional Covered Parties pursuant to Sections 106 and 107 of CERCLA, 42 U.S.C. 9606 and 9607, relating to Operable Unit 1. The EPA's covenants not to sue are subject to reservations. The settlement agreements also provide the Purchaser, Respondents, and Additional Covered Parties with protection from contribution actions or claims as provided by Section 113(f)(2) of CERCLA, 42 U.S.C. 9613(f)(2).

The EPA is providing notice of the proposed ASAOC in accordance with Section 122(i) of CERCLA, 42 U.S.C. 9622(i), which requires the Administrator to provide notice and an opportunity for comment when the EPA proposes to settle a claim pursuant to

Section 122(h) of CERCLA, 42 U.S.C. 9622(h). The EPA is providing notice of the proposed PPA in accordance with the terms of the PPA. Section 117(c) of CERCLA, 42 U.S.C. 9617(c), and 40 CFR 300.435(c)(2)(i) require EPA to issue an ESD when a settlement differs in any significant respect but does not fundamentally alter the remedy selected in the Record of Decision with respect to scope, performance, or cost. A formal public comment period is not required for an ESD.

Due to the interdependent nature of the three documents included in this notice, the EPA is requesting comment on all three documents simultaneously. The EPA will consider all comments received and may modify or withdraw its consent to the settlements if comments received disclose facts or considerations that indicate that the proposed settlements and proposed ESD are inappropriate, improper, or inadequate.

Douglas Ballotti,

Director, Superfund & Emergency Management Division, Region 5.

[FR Doc. 2022-09359 Filed 5-3-22; 8:45 am]

BILLING CODE 6560-50-P

FEDERAL DEPOSIT INSURANCE CORPORATION

Sunshine Act Meetings

TIME AND DATE: 10:00 a.m. on Thursday, May 5, 2022.

PLACE: The meeting is open to the public. Out of an abundance of caution related to current and potential coronavirus developments, the public's means to observe this Board meeting will be via a Webcast live on the internet and subsequently made available on-demand approximately one week after the event. Visit <https://youtu.be/FeRm7b-Xnss> to view the meeting. If you need any technical assistance, please visit our Video Help page at: <https://www.fdic.gov/video.html>.

Observers requiring auxiliary aids (e.g., sign language interpretation) for this meeting should call 703-562-2404 (Voice) or 703-649-4354 (Video Phone) to make necessary arrangements.

STATUS: Open.

MATTERS TO BE CONSIDERED: Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that the Federal Deposit Insurance Corporation's Board of Directors will meet in open session to consider the following matter:

Discussion Agenda: Memorandum and resolution re: Notice of Proposed

Rulemaking on Revisions to the Community Reinvestment Act Regulations.

CONTACT PERSON FOR MORE INFORMATION: Requests for further information concerning the meeting may be directed to Debra A. Decker, Executive Secretary of the Corporation, at 202-898-8748.

Dated at Washington, DC, on May 2, 2022.
Federal Deposit Insurance Corporation.

James P. Sheesley,

Assistant Executive Secretary.

[FR Doc. 2022-09639 Filed 5-2-22; 11:15 am]

BILLING CODE 6714-01-P

FEDERAL ELECTION COMMISSION

Sunshine Act Meetings

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 87 FR 23862.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: Tuesday, April 26, 2022 at 10:00 a.m. and its continuation at the conclusion of the open meeting on April 28, 2022.

CHANGES IN THE MEETING: Information the premature disclosure of which would be likely to have a considerable adverse effect on the implementation of a proposed Commission action.

* * * * *

CONTACT FOR MORE INFORMATION: Judith Ingram, Press Officer. Telephone: (202) 694-1220.

Authority: Government in the Sunshine Act, 5 U.S.C. 552b.

Laura E. Sinram,

Acting Secretary and Clerk of the Commission.

[FR Doc. 2022-09674 Filed 5-2-22; 4:15 pm]

BILLING CODE 6715-01-P

FEDERAL ELECTION COMMISSION

Sunshine Act Meetings

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 87 FR 24162.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: Thursday, April 28, 2022 at 10:00 a.m.

Hybrid meeting: 1050 First Street NE, Washington, DC (12th Floor) and virtual.

CHANGES IN THE MEETING: *The following matter was also considered:*

Audit Division Recommendation Memorandum on the UtePAC (A19-07).

CONTACT PERSON FOR MORE INFORMATION: Judith Ingram, Press Officer. Telephone: (202) 694-1220.

Authority: Government in the Sunshine Act, 5 U.S.C. 552b.

Laura E. Sinram,

Acting Secretary and Clerk of the Commission.

[FR Doc. 2022–09667 Filed 5–2–22; 4:15 pm]

BILLING CODE 6715–01–P

FEDERAL TRADE COMMISSION

[File No. 221 0002]

Hikma Pharmaceuticals PLC/Custopharm, Inc.; Analysis of Agreement Containing Consent Orders To Aid Public Comment

AGENCY: Federal Trade Commission.

ACTION: Proposed consent agreement; request for comment.

SUMMARY: The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis of Proposed Consent Orders to Aid Public Comment describes both the allegations in the complaint and the terms of the consent orders—embodied in the consent agreement—that would settle these allegations.

DATES: Comments must be received on or before June 3, 2022.

ADDRESSES: Interested parties may file comments online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Please write: “Hikma/Custopharm; File No. 221 0002” on your comment and file your comment online at <https://www.regulations.gov> by following the instructions on the web-based form. If you prefer to file your comment on paper, please mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC–5610 (Annex D), Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Steven Wilensky (202–326–2650), Bureau of Competition, Federal Trade Commission, 400 7th Street SW, Washington, DC 20024.

SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing a consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis of Agreement Containing

Consent Orders to Aid Public Comment describes the terms of the consent agreement and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC website at this web address: <https://www.ftc.gov/news-events/commission-actions>.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before June 3, 2022. Write “Hikma/Custopharm; File No. 221 0002” on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the <https://www.regulations.gov> website.

Due to protective actions in response to the COVID–19 pandemic and the agency’s heightened security screening, postal mail addressed to the Commission will be delayed. We strongly encourage you to submit your comments online through the <https://www.regulations.gov> website.

If you prefer to file your comment on paper, write “Hikma/Custopharm; File No. 221 0002” on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW, Suite CC–5610 (Annex D), Washington, DC 20580.

Because your comment will be placed on the publicly accessible website at <https://www.regulations.gov>, you are solely responsible for making sure your comment does not include any sensitive or confidential information. In particular, your comment should not include sensitive personal information, such as your or anyone else’s Social Security number; date of birth; driver’s license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure your comment does not include sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any “trade secret or any commercial or financial information which . . . is privileged or confidential”—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—including competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Comments containing material for which confidential treatment is requested must be filed in paper form, must be clearly labeled “Confidential,” and must comply with FTC Rule 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c). Your comment will be kept confidential only if the General Counsel grants your request in accordance with the law and the public interest. Once your comment has been posted on <https://www.regulations.gov>—as legally required by FTC Rule 4.9(b)—we cannot redact or remove your comment from that website, unless you submit a confidentiality request that meets the requirements for such treatment under FTC Rule 4.9(c), and the General Counsel grants that request.

Visit the FTC website at <https://www.ftc.gov> to read this Notice and the news release describing this matter. The FTC Act and other laws the Commission administers permit the collection of public comments to consider and use in this proceeding, as appropriate. The Commission will consider all timely and responsive public comments it receives on or before June 3, 2022. For information on the Commission’s privacy policy, including routine uses permitted by the Privacy Act, see <https://www.ftc.gov/site-information/privacy-policy>.

Analysis of Agreement Containing Consent Orders To Aid Public Comment

The Federal Trade Commission (“Commission”) has accepted, subject to final approval, an Agreement Containing Consent Order (“Consent Agreement”) from Hikma Pharmaceuticals PLC (“Hikma”), Custopharm, Inc. (“Custopharm”), Water Street Healthcare Partners, LLC (“Water Street”), Water Street Healthcare Partners III, L.P. (“Fund III”), Water Street Healthcare Partners IV (“Fund IV”), L.P., and Long Grove Pharmaceuticals, LLC (“Long Grove”) (collectively, “Respondents”). The purpose of the Consent Agreement is to remedy the anticompetitive effects that would likely result from Hikma’s acquisition of Custopharm (“the Proposed Acquisition”). Pursuant to an agreement dated September 27, 2021, Hikma proposes to acquire Custopharm in a transaction valued at approximately \$375 million. As part of the Proposed Acquisition, Custopharm agreed to carve out one of its pipeline products, injectable triamcinolone acetonide